Sanofi and GlaxoSmithKline (GSK) have signed a letter of intent for a partnership focused on developing an adjuvanted vaccine for Covid-19.
While Sanofi and GSK are also working separately to enable vaccines for the viral infection, the latest alliance is intended to combine their respective technologies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
